The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations
Open accessAbstract
Background Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure. Objective We sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school. Methods A 3-arm, randomized, double-blind, double placebo-controlled, multicenter clinical trial was conducted among inner-city asthmatic children aged 6 to 17 years with 1 or more recent exacerbations (clincaltrials.gov #NCT01430403). Guidelines-based therapy was continued over a 4- to 9-month run-in phase and a 4-month intervention phase. In a subset the effects of omalizumab on IFN-α responses to rhinovirus in PBMCs were examined. Results Before the falls of 2012 and 2013, 727 children were enrolled, 513 were randomized, and 478 were analyzed. The fall exacerbation rate was significantly lower in the omalizumab versus placebo arms (11.3% vs 21.0%; odds ratio [OR], 0.48; % CI, 0.25–.92), but there was no significant difference between omalizumab and ICS boost (8.4% vs 11.1%; OR, 0.73; 95% CI, 0.33–1.64). In a prespecified subgroup analysis, among participants with an exacerbation during the run-in phase, omalizumab was significantly more efficacious than both placebo (6.4% vs 36.3%; OR, 0.12; 95% CI, 0.02–0.64) and ICS boost (2.0% vs 27.8%; OR, 0.05; 95% CI, 0.002–0.98). Omalizumab improved IFN-α responses to rhinovirus, and within the omalizumab group, greater IFN-α increases were associated with fewer exacerbations (OR, 0.14; 95% CI, 0.01–0.88). Adverse events were rare and similar among arms. Conclusions Adding omalizumab before return to school to ongoing guidelines-based care among inner-city youth reduces fall asthma exacerbations, particularly among those with a recent exacerbation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma
Program, P., & theDiagnosis, T. E. P. O. (1997) · Cited by 4,926
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
(2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.029 · Cited by 2,181
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Wark, P. A. B., Johnston, S. L., Bucchieri, F., Powell, R., Puddicombe, S., Laza-Stanca, V., Holgate, S. T., & Davies, D. E. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041901 · Cited by 1,235
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Self-citationRandomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H. E., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 884
Self-citationMorosco, G., & Kiley, J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.09.043 · Cited by 867
Role of viral respiratory infections in asthma and asthma exacerbations
Busse, W. W., Lemanske, R. F., & Gern, J. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61380-3 · Cited by 750
Self-citation
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
Asthma Exacerbations: Pathogenesis, Prevention, and Treatment
Castillo, J. R., Peters, S. P., & Busse, W. W. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.05.001 · Cited by 544
Self-citationInternational consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Role of viral infections in the development and exacerbation of asthma in children
Jartti, T., & Gern, J. E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.003 · Cited by 474
Self-citationMcGregor, M. C., Krings, J. G., Nair, P., & Castro, M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1944ci · Cited by 432
Eosinophilic and Noneosinophilic Asthma
Carr, T. F., Zeki, A. A., & Kraft, M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201611-2232pp · Cited by 351
Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells
Palomares, O., Akdis, M., Martín‐Fontecha, M., & Akdis, C. A. (2017) · Immunological Reviews · doi:10.1111/imr.12555 · Cited by 330
EAACI Biologicals Guidelines—Recommendations for severe asthma
Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., et al. (2021) · Allergy · doi:10.1111/all.14425 · Cited by 275
Self-citationGuilbert, T. W., Bacharier, L. B., & Fitzpatrick, A. M. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.06.022 · Cited by 216
Del Giacco, S. R., Bakirtas, A., Bel, E., Custovic, A., Diamant, Z., Hamelmann, E., Heffler, E., Kalayci, Ö., Saglani, S., Sergejeva, S., et al. (2017) · Allergy · doi:10.1111/all.13072 · Cited by 130
“This synergism has been indirectly confirmed in a study showing that preseasonal anti-IgE-targeted therapy with omalizumab decreases seasonal exacerbations of asthma (‘back-to-school asthma’), which are almost certainly (rhino) virus-induced (25).”
ResultRamratnam, S. K., Bacharier, L. B., & Guilbert, T. W. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.04.031 · Cited by 119
Disaggregating asthma: big investigation versus big data
Belgrave, D., Henderson, J., Simpson, A., Buchan, I., Bishop, C., & Custovic, A. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.11.003 · Cited by 67
Edwards, M. R., Saglani, S., Schwarze, J., Skevaki, C., Smith, J. A., Ainsworth, B., Almond, M., Andreakos, E., Belvisi, M. G., Chung, K. F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02448-2016 · Cited by 55
Altman, M. C., Beigelman, A., Ciaccio, C., Gern, J. E., Heymann, P. W., Jackson, D. J., Kennedy, J. L., Kloepfer, K., Lemanske, R. F., McWilliams, L. M., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.12.904 · Cited by 37
Self-citation
Metadata
- Authors
- Teach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes, S. J., Calatroni, A., Wildfire, J. J., Gergen, P. J., Cohen, R. T., Pongracic, J. A., Kercsmar, C. M., Khurana Hershey, G. K., Gruchalla, R. S., Liu, A. H., Zoratti, E. M., Kattan, M., Grindle, K. A., Gern, J. E., Busse, W. W., & Szefler, S. J.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 136
- Issue
- 6
- Pages
- 1476-1485
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W1876031798
- Cited by
- 537
- References
- 33
- FWCI
- 36.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.